Core Points - The company is Wuxi Chison Medical Technologies Co., Ltd., established in accordance with the Company Law of the People's Republic of China and other relevant regulations [5][6] - The company was registered with the China Securities Regulatory Commission (CSRC) on October 28, 2019, and publicly issued 20 million ordinary shares, listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 3, 2019 [5][6] - The registered capital of the company is RMB 112,124,537.00 [5] - The company's business scope includes research, development, manufacturing, sales, and maintenance of medical devices, software development, and import-export of various goods and technologies [5][6] Company Structure - The company operates as a permanent joint-stock company with a governance structure that includes a chairman who also serves as the legal representative [5][6] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [6] - The company has established a Communist Party organization to conduct activities in accordance with the Party's regulations [6] Share Issuance and Management - The company issues shares in a manner that ensures equal rights for all shares of the same category, with a nominal value of RMB 1 per share [7][9] - The total number of shares issued by the company is 112,124,537, all of which are ordinary shares [9] - The company may not provide financial assistance for others to acquire its shares, except for employee stock ownership plans [9][10] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in shareholder meetings, where they can exercise voting rights [17][19] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not misuse their rights to harm the company or other shareholders [22][43] - The company must disclose information regarding significant transactions and ensure that shareholder meetings are conducted in compliance with legal requirements [19][30]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-025 无锡祥生医疗科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 无 二、 会议审议事项 本次提交股东大会审议的议案已分别经公司第三届董事会第十三次会议审 议通过和第三届监事会第十二次会议审议通过，具体内 ...

Core Viewpoint - Wuxi Xiangsheng Medical Technology Co., Ltd. is actively implementing a "Quality Improvement and Efficiency Enhancement" action plan to enhance investor returns and strengthen its core competitiveness through continuous innovation and talent development [1][2]. Group 1: Innovation and R&D - The company has maintained a research and development (R&D) personnel ratio of 34.3%, with 178 R&D staff, averaging over 10 years of experience, contributing to sustained innovation [1]. - As of the reporting period, the company holds 391 authorized patents, including 158 invention patents and 99 software copyrights, demonstrating its strong R&D capabilities [2]. - The company has accelerated its international product registration process, obtaining 43 new foreign market access licenses during the reporting period, thereby expanding its overseas market share [2]. Group 2: Commercialization and Market Presence - The company showcased its full range of products and AI-assisted diagnostic solutions at over 70 global industry events, enhancing brand exposure and clinical value [2]. - The "SonoGlobal 2025" agent conference and the "Evergreen Elite Project" were launched to upgrade core partners' capabilities from product sales to solution delivery, establishing a sustainable strategic cooperation system [2]. Group 3: Investor Communication and Disclosure - The company has established a comprehensive information disclosure management system to fulfill its obligations and has actively communicated with investors through various channels [3][4]. - Regular performance briefings and visual presentations of reports have been implemented to enhance investor understanding of the company's operations [4]. Group 4: Investor Returns - Since its listing in 2019, the company has maintained an average dividend payout ratio exceeding 65%, with a total dividend distribution of RMB 464 million [5]. - For the 2024 fiscal year, the company plans to distribute cash dividends of RMB 10 per 10 shares, totaling RMB 112 million, which represents 79.62% of the net profit attributable to shareholders [5]. Group 5: Corporate Governance - The company emphasizes the importance of a sound governance structure and effective internal control systems to enhance operational compliance and decision-making [6]. - The company has organized training for key personnel to ensure compliance with regulations and improve understanding of market dynamics [6].

Group 1 - The company has decided to abolish the supervisory board and transfer its responsibilities to the audit committee of the board of directors, in accordance with the revised Company Law and relevant regulations [1][2][3] - The proposed amendments to the Articles of Association will be submitted for approval at the company's first extraordinary general meeting of 2025 [1][3] - The company will also revise, abolish, and establish certain internal governance systems to enhance its governance structure [3][5] Group 2 - The supervisory board will continue to fulfill its supervisory duties until the general meeting approves the abolition [2] - The amendments to the Articles of Association include changes in terminology from "supervisory board" to "audit committee" and related adjustments [2][3] - The revised Articles of Association will be disclosed on the Shanghai Stock Exchange website following approval [3] Group 3 - The company aims to improve its governance structure and ensure compliance with the latest legal and regulatory requirements through the proposed changes [3][5] - Some internal governance systems will require shareholder approval, while others will take effect after board approval [5][6] - The company will ensure that the revised governance systems align with the updated Articles of Association [5][6]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-021 无锡祥生医疗科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 (一) 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意无锡祥生医疗科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2019]2018 号）核准，无锡祥生医疗科技 股份有限公司（以下简称"公司"）于 2019 年 11 月向社会公开发行人民币普通股 （A 股）20,000,000 股，每股发行价格为人民币 50.53 元，募集资金总额为人民 币 1,010,600,000.00 元 ， 扣 除 发 行 费 用 后 实 际 募 集 资 金 净 额 为 人 民 币 业经容诚会计师事务所（特殊普通合伙）会验字[2019]8172 号《验资报告》验证。 公司对募集资金采取了专户存储管理。 (二) 本年度募集资金使用金额及年末余额 截至 2025 年 6 月 30 日，公司累计使用募集资金人民币 743,396,639.01 元投 入募 ...

Core Viewpoint - The document outlines the selection and appointment procedures for accounting firms by Wuxi Xiangsheng Medical Technology Co., Ltd, ensuring compliance with relevant laws and regulations to maintain financial information quality and protect shareholder interests [1][2][3]. Group 1: General Principles - The selection of accounting firms must comply with the Company Law, Securities Law, and relevant regulations, ensuring the quality of financial information and protecting shareholder interests [1]. - The appointment process requires approval from the Board of Directors and the Shareholders' Meeting, prohibiting any interference from controlling shareholders before these approvals [2][3]. Group 2: Quality Requirements for Accounting Firms - Selected accounting firms must possess qualifications related to securities and futures, have a good record of professional quality, and meet specific criteria such as independent legal status and a solid internal management system [5]. - Firms must have no significant administrative penalties related to securities and futures in the past three years and must be familiar with relevant financial laws and regulations [5]. Group 3: Selection Procedures - The Audit Committee is responsible for the selection of accounting firms, including proposing the selection process, reviewing selection documents, and evaluating the firms based on established criteria [3][4]. - The selection process must be competitive and fair, utilizing methods such as competitive negotiations, public bidding, and invitation bidding [5][6]. Group 4: Evaluation and Reporting - The evaluation of accounting firms must consider various factors, including audit fees, qualifications, and quality management levels, with specific weightings assigned to each criterion [7][13]. - The Audit Committee must submit an annual evaluation report on the performance of the appointed accounting firm to the Board of Directors [4][9]. Group 5: Special Provisions for Reappointment - The company must reappoint accounting firms under specific circumstances, such as significant quality defects or inability to meet audit deadlines [21][22]. - The Audit Committee must investigate the reasons for reappointment and ensure compliance with quality standards [22][23]. Group 6: Supervision and Penalties - The company must maintain proper documentation of the selection and appointment processes for at least ten years, ensuring compliance with legal and regulatory requirements [30]. - The Audit Committee is responsible for monitoring the selection process and reporting any violations to the Board of Directors [34].

无锡祥生医疗科技股份有限公司 董事、高级管理人员离职管理制度 第一章 总则 第一条 为规范无锡祥生医疗科技股份有限公司（以下简称"公司"）董事、高级管 理人员离职管理，保障公司治理结构的稳定性和股东合法权益，根据《中华人民共和 国公司法》（以下简称"《公司法》"）等法律法规、规范性文件及《无锡祥生医疗科技 股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实际情况，制定本 制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员因任期届满、 辞任、辞职、被解除职务或者其他原因离职的情形。 第二章 离职情形与程序 第三条 公司董事可以在任期届满以前提出辞任，董事辞任应当向公司提交书面辞 职报告，辞职报告中应说明辞任原因，公司收到辞职报告之日辞任生效。 第四条 公司董事任期届满未获连任的，自股东会决议通过之日自动离职。 第五条 公司高级管理人员可以在任期届满以前提出辞职，有关高级管理人员辞职 的具体程序和办法由其与公司之间的劳动合同规定。 第六条 如存在下列情形，在改选出的董事就任前，原董事仍应当依照法律、行政 法规、部门规章和《公司章程》的规定，履行董事职务，但存在相关法规另有规定的 除 ...

Core Points - The article outlines the information disclosure and exemption management system of Wuxi Xiangsheng Medical Technology Co., Ltd, aiming to ensure compliance with legal obligations and protect investors' rights [1][2] - The company is required to disclose information in accordance with relevant regulations, but may defer or exempt disclosure under specific circumstances [1][2] - The internal management procedures for deferring or exempting disclosures are detailed, including the roles of the board of directors and the secretary [4][5] Chapter Summaries Chapter 1: General Principles - The system is established to regulate information disclosure and exemption behaviors, ensuring compliance with laws and protecting investor rights [1] - The company must assess whether information can be deferred or exempted based on specific criteria outlined in the regulations [1][2] Chapter 2: Applicable Situations and Conditions - Information may be exempted from disclosure if it involves state secrets or commercial secrets that could lead to unfair competition or harm to the company or others [2] - If the reasons for deferring or exempting disclosure are eliminated, the company must promptly disclose the information [2] Chapter 3: Internal Management Procedures for Disclosure Deferral and Exemption - The board of directors leads the management of deferral and exemption matters, with the secretary coordinating the process [4] - A formal application process is required, including documentation and internal approvals before any deferral or exemption is enacted [5] Chapter 4: Responsibilities and Penalties - The company must establish a responsibility accountability mechanism for any non-compliance with the disclosure system [6][7] - Individuals responsible for improper deferral or exemption may face consequences if it leads to negative impacts on the company or investors [7] Chapter 5: Supplementary Provisions - The system must align with existing stock exchange rules and relevant laws [7] - The board of directors is responsible for interpreting the system, which takes effect upon approval [7]

无锡祥生医疗科技股份有限公司 内幕信息知情人登记制度 第一章 总则 第三条 未经董事会批准同意, 公司任何部门和个人不得向外界泄露、报道、 传送有关公司内幕信息及信息披露的内容。对外报道、传送的文件、 音像及光盘等涉及内幕信息及信息披露的内容的资料, 须经董事会的 审核同意, 方可对外报道、传送。 第四条 公司董事、高级管理人员和公司各部门、分公司、控股子公司及公司 能够对其实施重大影响的参股公司以及其他内幕信息知情人都应做 好内幕信息的保密工作。 第五条 公司董事、高级管理人员和其他内幕信息知情人在信息披露前, 应当 将该信息的知情者控制在最小范围内, 不得泄漏公司内幕信息, 不得 进行内幕交易或者配合他人操纵公司股票及其衍生品种交易价格。 第六条 本制度所指内幕信息是指涉及公司的经营、财务或者对公司证券及其 衍生品种的市场价格有重大影响的尚未公开的信息。尚未公开是指公 司尚未在公司章程指定的信息披露刊物或网站上正式公开披露。 第七条 本制度所指内幕信息的范围包括但不限于: (1) 公司的经营方针和经营范围的重大变化; (2) 公司的重大投资行为, 公司在一年内购买、出售重大资产超过公 司资产总额百分之三十 ...

无锡祥生医疗科技股份有限公司 防范控股股东、实际控制人及其他关联方资金占用管理办法 第一章 总则 (一) 用于抵偿的资产必须属于公司同一业务体系, 并有利于增强公 司独立性和核心竞争力, 减少关联交易, 不得是尚未投入使用 的资产或者没有客观明确账面净值的资产。 (二) 公司应当聘请符合《证券法》规定的中介机构对符合以资抵债条 件的资产进行评估, 以资产评估值或者经审计的账面净值作为 以资抵债的定价基础, 但最终定价不得损害公司利益, 并充分 考虑所占用资金的现值予以折扣。审计报告和评估报告应当向 披露。 (三) 独立董事专门会议应当就公司关联方以资抵债方案进行审议, 或者聘请符合《证券法》规定的中介机构出具独立财务顾问报告。 (四) 公司关联方以资抵债方案须经股东会审议批准, 关联方股东应 当回避投票。 第三章 公司董事会、高管人员的责任 第十三条 公司董事、高级管理人员对维护公司资金安全负有法定义务和责任, 应 按照公司法及公司章程等有关规定勤勉尽职, 切实履行防止控股股东、 实际控制人及其他关联方占用公司资金行为的职责。 第十四条 公司董事长是防止资金占用、资金占用清欠工作的第一责任人。 第十五条 公司 ...